TipRanks
Seelos Therapeutics (DE:NXE)
FRANKFURT:NXE
Germany Market
NXE
Seelos Therapeutics
RESEARCH TOOLSreports

Seelos Therapeutics (NXE) Income Statement

2 Followers

Seelos Therapeutics Income Statement

Last quarter (Q2 2023), Seelos Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Seelos Therapeutics's net income was $-29.50M. See Seelos Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ ―$ ―$ ―$ ―$ ―
Gross Profit
$ 121.00K$ 113.00K$ ―$ ―$ ―
Operating Expenses
$ ―$ ―$ ―$ ―$ ―
Depreciation and Amortization
$ ―$ ―$ ―$ ―$ ―
EBITDA
$ -73.47M$ -63.10M$ -18.94M$ -51.23M$ -9.18M
Operating Income
$ -70.80M$ -61.56M$ -18.76M$ -29.75M$ -9.15M
Other Income/Expenses
$ ―$ ―$ ―$ ―$ ―
Pretax Income
$ ―$ ―$ ―$ ―$ ―
Net Income
$ -73.53M$ -66.05M$ -19.10M$ -51.26M$ -9.24M
Per Share Metrics
Basic EPS
$ ―$ ―$ ―$ ―$ ―
Diluted EPS
$ ―$ ―$ ―$ ―$ ―
Weighted Average Shares Outstanding
 ― ― ― ― ―
Weighted Average Shares Outstanding (Diluted)
 ― ― ― ― ―

Seelos Therapeutics Earnings and Revenue History